Analyzing Science 37 (SNCE) and Its Rivals

Science 37 (NASDAQ:SNCEGet Rating) is one of 41 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare Science 37 to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.

Institutional & Insider Ownership

58.6% of Science 37 shares are held by institutional investors. Comparatively, 58.4% of shares of all “Commercial physical research” companies are held by institutional investors. 4.4% of Science 37 shares are held by insiders. Comparatively, 11.9% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Science 37 has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Science 37’s peers have a beta of 5.68, indicating that their average share price is 468% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Science 37 and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Science 37 0 0 5 0 3.00
Science 37 Competitors 41 611 1211 24 2.65

Science 37 presently has a consensus price target of $10.00, suggesting a potential upside of 584.93%. As a group, “Commercial physical research” companies have a potential upside of 47.82%. Given Science 37’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Science 37 is more favorable than its peers.


This table compares Science 37 and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Science 37 -56.12% -87.95% -52.86%
Science 37 Competitors -239.39% -12.45% -6.19%

Earnings & Valuation

This table compares Science 37 and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Science 37 $59.60 million -$94.33 million -0.41
Science 37 Competitors $2.80 billion $97.54 million -18.09

Science 37’s peers have higher revenue and earnings than Science 37. Science 37 is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


Science 37 peers beat Science 37 on 7 of the 13 factors compared.

Science 37 Company Profile

(Get Rating)

Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

Receive News & Ratings for Science 37 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Science 37 and related companies with's FREE daily email newsletter.